Through the collaboration, researchers at UT Austin will formulate hemagglutinin and neuraminidase proteins using TFF's thin-film freezing technology. Then, researchers at the University of Georgia's Center for Vaccines and Immunology will evaluate the immune responses to the compounds.

The research resulting from the collaboration could lead to a vaccine that protects people against multiple forms of influenza, including seasonal and pandemic flus.

Could a MERS vaccine candidate be the answer for COVID-19?
As researchers urgently work to develop vaccines to prevent COVID-19, many strategies have been considered. Now, a parainfluenza virus 5-based vaccine...

It's time to enlist research labs in the COVID-19 fight
Careful incorporation of research laboratories into the COVID-19 testing effort could increase capacity in the U.S. and globally, writes molecular diagnostics...

Are masks effective at preventing the spread of SARS-CoV-2?
Contradictory messages over the best methods to limit the spread of SARS‑CoV‑2 have been shared with the public in past months. This has prompted...

COVID-19 shuts down research labs as concern grows among scientists
Almost half of all scientific research labs that participated in a recent survey were shut down due to concerns about the COVID-19 outbreak. Survey results...

SARS-CoV-2 vaccine utilizing microneedle arrays appears in the literature
Within four weeks of the SARS-CoV-2 spike sequence becoming available, researchers from the University of Pittsburgh School of Medicine developed immunogens...